Search Results - "Joseph, Tami"

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials by Viney, Nicholas J, BSc, van Capelleveen, Julian C, MD, Geary, Richard S, PhD, Xia, Shuting, MS, Tami, Joseph A, PharmD, Yu, Rosie Z, PhD, Marcovina, Santica M, Prof, Hughes, Steven G, MD, Graham, Mark J, MS, Crooke, Rosanne M, PhD, Crooke, Stanley T, MD, Witztum, Joseph L, Prof, Stroes, Erik S, Prof, Tsimikas, Sotirios, Prof

“…Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific…”
Get full text

Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha by Sewell, K Lea, Geary, Richard S, Baker, Brenda F, Glover, Josephine M, Mant, Timothy G K, Yu, Rosie Z, Tami, Joseph A, Dorr, F Andrew

“…ISIS 104838 is a 20-mer phosphorothioate antisense oligonucleotide (ASO) that binds tumor necrosis factor-alpha (TNF-alpha) mRNA. It carries a 2'-methoxyethyl…”
Get more information

A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis by Walter P Maksymowych, Warren D Blackburn, Jr, Joseph A Tami, William R Shanahan, Jr

“…OBJECTIVE: To determine the safety of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 (ICAM-1) (ISIS 2302), administered in an intensive…”
Get full text

Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection by KAHAN, Barry D, STEPKOWSKI, Stanislaw, KILIC, Murat, KATZ, Steven M, VAN BUREN, Charles T, WELSH, Maria S, TAMI, Joseph A, SHANAHAN, William R

“…ISIS 2302, an antisense oligonucleotide that inhibits the expression of human intercellular adhesion molecule (ICAM)-1, was evaluated in combination with a…”
Get full text

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease by Yacyshyn, Bruce R., Bowen-Yacyshyn, Mary Beth, Jewell, Lawrence, Tami, Joseph A., Bennett, C.Frank, Kisner, Daniel L., Shanahan, William R.

“…Background & Aims: Intercellular adhesion molecule 1 (ICAM-1) plays an important role in the trafficking and activation of leukocytes and is up-regulated in…”
Get full text

288 Clinical Integration of Multijet Fusion 3D Printing-Based Bolus for VMAT Chest Wall Patients by Joseph, Tami, Clancey, James, Hurley, Jennifer, Sibley, Allison, D’souza, Malgorzata, Orton, Elizabeth, Cherpak, Amanda, Monajemi, Thalat

Get full text

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk by Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce, Figueroa, Amparo L, Alexander, Veronica J, Tami, Joseph, Witztum, Joseph L, Geary, Richard S, O’Dea, Louis St L, Tsimikas, Sotirios, Gaudet, Daniel

“…Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an…”
Get full text

APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia by Prohaska, Thomas A., Alexander, Veronica J., Karwatowska-Prokopczuk, Ewa, Tami, Joseph, Xia, Shuting, Witztum, Joseph L., Tsimikas, Sotirios

“…•Volanesorsen is an ASO targeting APOC3 that potently reduces triglyceride levels.•Hepatic fat fraction was evaluated by MRI in 3 RCTs: APPROACH, BROADEN and…”
Get full text

Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study by Oral, Elif A., Garg, Abhimanyu, Tami, Joseph, Huang, Eric A., O'Dea, Louis St.L., Schmidt, Hartmut, Tiulpakov, Anatoly, Mertens, Ann, Alexander, Veronica J., Watts, Lynnetta, Hurh, Eunju, Witztum, Joseph L., Geary, Richard S., Tsimikas, Sotirios

“…•Managing high TG levels in familial partial lipodystrophy (FPLD) is challenging.•The antisense oligonucleotide volanesorsen can reduce apolipoprotein C-III…”
Get full text

ApoC-III Levels Correlate with Insulin Resistance and HbA1c in Familial Partial Lipodystrophy—Observations from the Broaden Study by Meral, Rasimcan, Digenio, Andres, Neidert, Adam H, Tami, Joseph, Oral, Elif A

“…Familial Partial Lipodystrophy (FPLD) is a rare genetic disorder with selective loss of adipose tissue from the periphery with an increase in ectopic fat…”
Get full text

Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study by Oral, Elif A, Garg, Abhimanyu, Tami, Joseph, Huang, Eric A, O'Dea, Louis St L, Schmidt, Hartmut, Tiulpakov, Anatoly, Mertens, Ann, Alexander, Veronica J, Watts, Lynnetta, Hurh, Eunju, Witztum, Joseph L, Geary, Richard S, Tsimikas, Sotirios

“…Volanesorsen, an antisense oligonucleotide, is designed to inhibit hepatic apolipoprotein C-III synthesis and reduce plasma apolipoprotein C-III and…”
Get full text

Intrapatient study comparing 3D printed bolus versus standard vinyl gel sheet bolus for postmastectomy chest wall radiation therapy by Robar, James L., Moran, Kathryn, Allan, James, Clancey, James, Joseph, Tami, Chytyk-Praznik, Krista, MacDonald, R. Lee, Lincoln, John, Sadeghi, Parisa, Rutledge, Robert

“…This patient study evaluated the use of 3-dimensional (3D) printed bolus for chest wall radiation therapy compared with standard sheet bolus with regard to…”
Get full text

Cloning of size-selected human immunoglobulin heavy-chain rearrangements from third complementarity-determining region fingerprint profiles by Raaphorst, F M, Tami, J, Sanz, I E

“…Methods have been developed to rapidly visualize the size distribution of third complementarity-determining regions (CDR3) in immunoglobulin (Ig) and T-cell…”
Get full text

High dose safety and pharmacokinetic study of ISIS 2302 in Crohn’s disease by Barish, Charles F, Goff, John, Dalke, Douglas, Gaspari, Michael, Tami, Joseph, Sewell, Lea, Yacyshyn, Bruce

Get full text

A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels by Yacyshyn, Bruce R., Chey, W.Y., Goff, J, Salzberg, B, Baerg, R, Buchman, A.L., Tami, Joseph A., Shanahan, William R.

Get full text

Human Ig heavy chain CDR3 regions in adult bone marrow pre-B cells display an adult phenotype of diversity: evidence for structural selection of DH amino acid sequences by Raaphorst, F M, Raman, C S, Tami, J, Fischbach, M, Sanz, I

“…Ig repertoires generated at various developmental stages differ markedly in diversity. It is well documented that Ig H chain genes in human fetal liver are…”
Get full text

Evaluation of biotechnology products by Tami, J, Evens, R P

“…Biotechnology products have had a substantial impact on the health care system, including cost and patient care. In some hospitals, agents produced by…”
Get more information

Introduction to immunology by McIntyre, W J, Tami, J A

“…The immune system is a complex network of components functioning to provide host defense. This network consists of immunologic cells and their products (e.g.,…”
Get more information

Analysis of helper T-cell specificity involved in the antibody response to the acetylcholine receptor by Tami, J A, Krolick, K A

Get more information

Immunology for the clinical pharmacist by Tami, J A

“…Major advances in the field of immunology within the past decade have led to greater understanding of the immune network. The immune system is finely balanced,…”
Get more information